Par Pacific Holdings reported strong Q3 2026 results with net income of $353.3 million and adjusted net income of $531.5 million, driven by a $187.2 million benefit from small refinery exemptions. The company plans to divest its 46% stake in Laramie Energy, expecting near-term cash proceeds of about $120 million by year-end. Refining segment margins improved significantly despite lower throughput, while the newly created Renewables segment posted its first profitable quarter. Par Pacific remains focused on operational reliability and customer service amid favorable market conditions.
Par Pacific Holdings' Q3 2026 results provide context for energy market watchers. For readers following energy stocks, here is Pluang's market snapshot as of Nov 04, 2026 04:21 WIB: Among 79 priced US energy stocks, 27 rose and 51 fell. Notable movers include Cenovus Energy Inc (CVE) at USD 30.68, down 6.29%, Sunrun Inc (RUN) at USD 8.75, up 6.06% with 42% sell and 58% buy order activity, and Kosmos Energy Ltd. (KOS) at USD 2.60, up 5.47% with 7% sell and 93% buy order activity.
Vencora has acquired CT InsureTech, a leading insurance technology provider with offices in London, Buenos Aires, and Mexico City. This acquisition strengthens Vencora's insurance technology offerings and expands its presence in Latin America and Eur...
Vencora has acquired CT InsureTech, a leading provider of insurance technology and services with offices in London, Buenos Aires, and Mexico City. This acquisition expands Vencora's portfolio and presence in Latin America and the UK, strengthening it...
The iShares MSCI USA Value Factor ETF has outperformed the S&P 500 over the past year, largely due to its heavy weighting in Micron, which accounts for about 19.23% of the fund. The ETF's sector neutrality rule results in a 40% technology allocation,...
Postal Realty Trust, Inc. announced a net income of $0.16 per diluted share for Q3 2026, driven by acquisitions of 145 USPS properties worth $82 million and a 25.2% increase in rental income year-over-year. The company raised its 2026 acquisition gui...
Crescent Biopharma awarded stock options for 11,775 shares to a new non-executive employee as part of an inducement plan approved by its Compensation Committee. The options have a 10-year term with an exercise price of $12.91, matching the closing sh...
